Calico’s fosigotifator was tested for amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease that affects nerve cells in the brain and spinal cord and leads to paralysis.

Calico's drug, called fosigotifator, is one of a handful run through a clinical trial platform at Massachusetts General Hospital, which disclosed fosigotifator's topline study results Monday.

Massachusetts General Hospital found neither AbbVie and Calico’s fosigotifator nor Denali’s DNL343 significantly slowed disease progression, causing misses on their respective primary endpoints.

Fosigotifator, an amyotrophic lateral sclerosis drug developed by Calico Life Sciences, a biotech company backed by Google's parent company Alphabet, failed to meet its primary endpoint ...

Google’s (GOOGL) anti-aging company Calico released disappointing trial results of its first ever drug. Calico’s fosigotifator was tested for amyotrophic lateral sclerosis (ALS), a fatal ...